(Total Views: 888)
Posted On: 01/07/2017 3:32:03 AM
Post# of 273254
OWC Pharmaceutical Research Corp. $OWCP News
Last updated 01/07/2017 - 0.1845
CFN Media Exclusive Interview with Jeffrey Friedland, Advisory Board Member for OWC Pharmaceutical Research
Jan 04, 2017
OTC Disclosure & News Service
-
CFN Media Exclusive Interview with Jeffrey Friedland, Advisory Board Member for OWC Pharmaceutical Research
SEATTLE, WA--(Marketwired - Jan 4, 2017) - CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an exclusive interview with Jeffrey Friedland, CEO of Intiva Inc. and member of the Advisory Board for OWC Pharmaceutical Research Corp. (OTCQB: OWCP).
Mr. Friedland, author of the book Marijuana: The World's Most Understood Plant, discusses the legal cannabis industry in general, the reasons why his company decided to invest in OWC Pharmaceutical Research, and the outlook for both OWC and the pharmaceutical side of the emerging industry moving forward.
Please follow the link to view the interview: http://www.cannabisfn.com/cfnvideo/?id=Q8qC1EFo
Learn how to become a CFN Media featured company, brand or entrepreneur: http://www.cannabisfn.com/become-featured-company/
Download the CFN Media iOS mobile app to access the world of cannabis from your smart phone: https://itunes.apple.com/us/app/cannabisfn/id...1&mt=8
Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively "OWC" or the "Company"
conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.
The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information, visit: http://www.owcpharma.com/
Disclaimer:
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and CannabisFN.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.
Contact:
Frank Lane
206 369 7050
flane@cannabisfn.com
Copyright © 2017 Marketwired. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
OWC Pharmaceutical Research Advisory Board Member to Participate in the First Bloomberg Intelligence Sponsored Cannabis Event
Nov 18, 2016
OTC Disclosure & News Service
-
OWC Pharmaceutical Research Advisory Board Member to Participate in the First Bloomberg Intelligence Sponsored Cannabis Event
Bloomberg's "Cannabis Trends & Legalization Implications" Will be Held Monday, November 21st in New York
PR Newswire
PETACH TIKVA, Israel, November 18, 2016
PETACH TIKVA, Israel, November 18, 2016 /PRNewswire/ --
PETACH TIKVA, Israel, November 18, 2016: OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company" , a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced that Jeffrey Friedland, a member of the Company's Advisory Board, will be participating in Bloomberg Intelligence's first cannabis-related event; Cannabis Trends & Legalization Implications.
(Logo: http://photos.prnewswire.com/prnh/20150311/734965-a )
(Logo: http://photos.prnewswire.com/prnh/20150311/734965-b )
Cannabis Trends & Legalization Implications will be held Monday, November 21st in New York City, and will explore the most important legal, medical and financial developments and issues associated with America's marijuana industry. The session will start with a panel of key players in the space, dissecting the implications and opportunities associated with cannabis decriminalization across the United States. It will be moderated by Kenneth Shea, Senior Consumer Products Analyst of Bloomberg Intelligence.
It is anticipated that Mr. Friedland, who is also the author of Marijuana: The World's Most Misunderstood Plant, will have the opportunity to highlight to event attendees the progress that OWC has made with its medical cannabis research in Israel, and the positive impact that OWC and other Israeli companies are having on state-licensed U.S. growers and extractors.
When asked about his participation in the Bloomberg event, Mr. Friedland stated, "I've been involved in the legal cannabis industry for several years now; including as the CEO of INTIVA Inc., an investor and operator of businesses in the global cannabis market. I view the cannabis industry as an emerging global market with several sectors, including medical, recreational, services and equipment, each with their own unique opportunities for investors and entrepreneurs. While many industry participants are very speculative, as the legalization of both recreational and medical cannabis spreads, I've concluded that the real money will be made by companies that not only harness science to differentiate their products, but are also able to get those products into the marketplace."
Friedland went on to say, "There are many cannabis companies that are publicly-traded, from GW Pharmaceuticals (GWPH) to smaller public companies such as OWC, which Intiva invested in during the summer of 2014 when OWC's research into the effects of cannabis on conditions including multiple myeloma, psoriasis and PTSD caught our attention; I joined the Company's advisory board earlier this year. OWC's recent announcements of partnerships to bring its cannabis-based topical psoriasis product to licensed markets in the US and EU are significant events for the Company, and indicate positive directions for the execution of their business model."
Subject to his schedule, Mr. Friedland may be available to meet privately with OWC shareholders to discuss his view of OWC's future.
About Bloomberg Intelligence
Bloomberg Intelligence is the research arm of Bloomberg L.P. It provides in-depth analysis and data sets on industries, companies and credit, government economic and litigation factors that impact decision making.
About Jeffrey Friedland
Jeffrey Friedland is an emerging market pioneer -- his firm, Friedland Global Capital, was one of the first American investment banks to establish a presence in China -- and he can now be found on the forefront of the cannabis movement. In his book, Marijuana: The World's Most Misunderstood Plant guides the reader through the plant's rich, and sometimes scandalous history, explains how and why cannabis affects us, describes the methods of breeding, cultivating and processing that plant, and perhaps most importantly, provides an overview of the most recent research into its potential of cannabinoid-based medicine.
Mr. Friedland was an owner of two retail cannabis stores in Colorado in the mountain resort towns of Breckenridge and Crested Butte, and a cannabis cultivation facility located south of Steamboat Springs. These businesses were featured in CNN's 2015 reality series, High Profits. He is also CEO of INTIVA Inc., a multi-faceted life sciences company in the worldwide legal cannabis industry that has established businesses and made investments in the cannabis industry in California, Colorado, Canada and Israel.
Mr. Friedland is also CEO of the financial services firm Friedland Global Capital, which provides corporate finance and strategic advisory services to entrepreneurial companies in emerging markets. He has been the CEO of a Nasdaq-listed company, a member of the board of directors and chairman of the audit committee of a New York Stock Exchange-listed company, and the chairman of the supervisory board of a company listed on the Regulated Market of the Frankfurt Stock Exchange. Mr. Friedland has been featured, interviewed or quoted in numerous publications including the Wall Street Journal, USA Today, The South China Morning Post (Hong Kong), NBC.com, Forbes, CNBC and its predecessor, Financial News Network, Bloomberg Information Radio, and Bloomberg TV. This is the second book he has written. His first book, All Roads Lead to China: An Investor Road Map to the World's Fastest Growing Economy, was published in 2014.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact Information:
In Israel:
Ziv Turner, Chief Executive Officer - One World Cannabis Ltd.
Email: ziv.turner@owcpharma.com
Tel: +972-(0)3-7582659
SOURCE OWC Pharmaceutical Research Corp.
Copyright © 2016 PR Newswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
OWC Pharmaceutical Research Corp to Submit Psoriasis Topical Cream IRB Safety Protocol to the Israeli National IRB ("Helsinki" Committee
Nov 15, 2016
OTC Disclosure & News Service
-
OWC Pharmaceutical Research Corp to Submit Psoriasis Topical Cream IRB Safety Protocol to the Israeli National IRB ("Helsinki" Committee
Final IRB ("Institutional Review Board" for safety study
PR Newswire
PETACH TIKVA, Israel, November 15, 2016
PETACH TIKVA, Israel, November 15, 2016 /PRNewswire/ --
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWCP" or the "Company" , thorough its Israeli based fully owned subsidiary, a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced it is submitting the final Psoriasis IRB safety protocol for the Israeli national IRB committee at the Health Minister office.
(Logo: http://photos.prnewswire.com/prnh/20150311/734965-b )
(Photo: http://photos.prnewswire.com/prnh/20161115/439488 )
The IRB protocol was first approved by the hospital which will perform the safety study and after obtaining its approval the IRB protocol is being submitted for approval to the national IRB committee. The national IRB committee is scheduled to ensemble at the beginning of December 2016.
Upon the expected approval of the safety protocol by the national committee, the company will immediately engage with the study which will last approximately 12 weeks.
Results are expected by the end of March 2016 and upon reaching satisfactory results the company intends to start production, marketing and sales in the US and EU in parallel to local IL efforts.
The Safety study is designed to test multiple escalating doses to determine the safety and tolerability of the medical grade cannabis cream on healthy volunteers. The psoriasis topical crème infused with active cannabinoids is a unique delivery-system product of OWC designed to be used for skin diseases, where the first application will be tested for safety and efficacy for Psoriasis. The efficacy studies have already been started and results are expected by the end of Jan 2017.
Psoriasis is an autoimmune disease that causes red, scaly patches to appear on the skin, and can be associated with other serious health conditions, including diabetes, heart disease and depression. The World Health Organization's 2016 Global Report on Psoriasis states that psoriasis is a serious global problem affecting at least 100 million individuals worldwide with estimated 8 million patients in the US. The report indicates the prevalence of psoriasis ranges from 0.09% in countries with warmer climates to 11.43% in Norway, where a colder climate prevails. The European market for psoriasis is estimated to be 15-20 Million patients.
Dr. Yehuda Baruch, the Company's CSO & Director of Research and Regulatory Affairs said, "Best to my knowledge this is the first Cannabis safety study that was submitted to the Israeli IRB national committee to be performed on healthy volunteers. I am also not aware of any other cannabis infused topical crème that was tested for safety, efficacy and bio-availability with approved IRB. That makes our products unique and valuable which matches exactly the company's vision and targets to develop approved, safe and effective active-cannabinoids products for medical treatments."
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively "OWC" or the "Company" conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.
The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information, visit: http://www.owcpharma.com/
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact Information:
In Israel:
Ziv Turner, Chief Executive Officer - One World Cannabis Ltd.
Email: ziv.turner@owcpharma.com
Tel: +972-(0)3-7582659
In the United States:
Jeffrey Friedland
Email: Jfriedland@owcpharma.com
Tel: +1-(646)-450-8909
SOURCE OWC Pharmaceutical Research Corp.
Copyright © 2016 PR Newswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
OWC Pharmaceutical Corporation Advisory Board Member, Jeffrey Friedland, Comments on the Election and the Possible Impact on the U.S. Cannabis Market
Nov 07, 2016
OTC Disclosure & News Service
-
OWC Pharmaceutical Corporation Advisory Board Member, Jeffrey Friedland, Comments on the Election and the Possible Impact on the U.S. Cannabis Market
Mr. Friedland Comments Included His Thoughts On The Potential For Benefit To The Company
PR Newswire
PETACH TIKVA, Israel, November 7, 2016
PETACH TIKVA, Israel, November 7, 2016 /PRNewswire/ --
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), through its Israeli based fully owned subsidiary, (collectively "OWC" or the "Company" a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, was featured in the comments of its Advisory Board member, Jeffrey Friedland. In addition to serving on the Company's Advisory Board, Mr. Friedland is the Chief Executive Officer of Intiva Inc., author of Marijuana: The World's Most Misunderstood Plant, and frequent keynote speaker for the cannabis industry.
(Logo: http://photos.prnewswire.com/prnh/20150311/734965-a )
(Logo: http://photos.prnewswire.com/prnh/20150311/734965-b )
Recently, Mr. Friedland commented on the pending election and the possible effects on the future of the cannabis industry, "Many entrepreneurs and investors have expressed their concerns to me regarding the outcome of Tuesday's U.S. presidential election, specifically whether the winner will have a positive or negative impact on the cannabis industry. Both Hillary Clinton and Donald Trump have stated that they will support the medical use of cannabis."
Mr. Friedland went on to say, "Regardless of the outcome of Tuesday's vote, I see no immediate change in the existing system of allowing state-licensed medical cannabis businesses, nor do I see any immediate change in the rescheduling of cannabis under the Controlled Substances Act…..What is more significant to the U.S. cannabis industry is Tuesday's outcome of voting in California and Nevada, where adult recreational use of cannabis is on the ballot. I'm expecting voters in both states to approve recreational cannabis."
Regarding Intiva's investment in OWC, Mr. Friedland had this to say, "The decision to invest in OWC during the summer of 2014 came after spending some time in Israel, where I concluded that the real money in the cannabis industry will be made by companies who create 'real pharmaceuticals based on real science.' I was impressed with OWC's management team; Dr. Yehuda Baruch, the Company's director of research, was the former head of Israel's medical cannabis program. I also found intriguing the early-stage research OWC had underway regarding trials of their proprietary cannabis-based formulations for the treatment of multiple myeloma and other conditions."
As for the potential effect of the election on OWC, Mr. Friedland added that if, as he expected, California and Nevada approved recreational cannabis, the Company had "plenty to gain from Tuesday's vote in the U.S……as OWC Pharmaceutical Research recently announced that it has entered into a U.S. license agreement with a Maryland-based company to bring its topical psoriasis cream to state-licensed businesses in the U.S. market….and the establishment of recreational cannabis businesses in California and Nevada would significantly increase the availability of medical cannabis for patients in those states.
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively "OWC" or the "Company" conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.
The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information, visit: http://www.owcpharma.com/
About Jeffrey Friedland
Jeffrey Friedland is an emerging market pioneer -- his firm, Friedland Global Capital, was one of the first American investment banks to establish a presence in China -- and he can now be found on the forefront of the cannabis movement. In his book, Marijuana: The World's Most Misunderstood Plant guides the reader through the plant's rich, and sometimes scandalous history, explains how and why cannabis affects us, describes the methods of breeding, cultivating and processing that plant, and perhaps most importantly, gives an overview of the most recent research into its potential within the word of medicine.
Mr. Friedland was an owner of two retail cannabis stores in Colorado in the mountain resort towns of Breckenridge and Crested Butte, and a cannabis cultivation facility located south of Steamboat Springs, which were featured in CNN's 2015 reality series, High Profits. He is also CEO of INTIVA Inc., a multi-faceted life sciences company in the worldwide legal cannabis industry. INTIVA has established operating businesses and made venture investments in the cannabis industry in California, Colorado, Canada and Israel.
Mr. Friedland is also CEO of the financial services firm Friedland Global Capital, which provides corporate finance and strategic advisory services to entrepreneurial companies in emerging markets. He has been the CEO of a Nasdaq-listed company, a member of the board of directors and chairman of the audit committee of a New York Stock Exchange-listed company, and the chairman of the supervisory board of a company listed on the Regulated Market of the Frankfurt Stock Exchange. Mr. Friedland has been featured, interviewed or quoted in numerous publications including the Wall Street Journal, USA Today, The South China Morning Post (Hong Kong), NBC.com, Forbes, CNBC and its predecessor, Financial News Network, Bloomberg Information Radio, and Bloomberg TV. This is the second book he has written. All Roads Lead to China: An Investor Road Map to the World's Fastest Growing Economy was published in 2014.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact Information:
In Israel
Ziv Turner, Chief Executive Officer - One World Cannabis Ltd.
Email: ziv.turner@owcpharma.com
Tel: +972(0)3-7582659
SOURCE OWC Pharmaceutical Research Corp.
Copyright © 2016 PR Newswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
OWC Pharmaceutical Research Corp Signs Investment and Joint Venture with Michepro Holdings Ltd
Nov 03, 2016
OTC Disclosure & News Service
-
OWC Pharmaceutical Research Corp Signs Investment and Joint Venture with Michepro Holdings Ltd
Initial Focus Will Be Commercialization of Company's Topical Psoriasis Treatment in the European Union
PR Newswire
PETACH TIKVA, Israel, November 3, 2016
PETACH TIKVA, Israel, November 3, 2016 /PRNewswire/ --
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWCP" or the "Company" , through its Israeli based fully owned subsidiary, a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced it has inked agreement for a combined JV & Private Placement of $300,000 with Michepro Holding Ltd a private family investment company organized under the laws of the state of Cyprus ("The Investor\ partner " .
(Logo: http://photos.prnewswire.com/prnh/20150311/734965-a )
(Photo: http://photos.prnewswire.com/prnh/20161103/435811 )
The Investor will be issued with 2,307,692 restricted shares of the Company's common stock (a price of $0.13 per share) with additional warrants to purchase 761,538 restricted shares at an exercise price of $0.25 per share for a period of 24 months, and additional warrants for 761,538 restricted shares at an exercise price of $0.40 per share for a period of 36 months. In addition to the investment, the parties will establish a joint venture, 75% to OWCP and 25% to Michepro Holding Ltd to promote, sell, market and distribute the Company's potential products in Europe, initially with the psoriasis treatment, to be followed with company's other therapies as they become available."
The World Health Organization's 2016 Global Report on Psoriasis states that psoriasis is a serious global problem affecting at least 100 million individuals worldwide. The report indicates the prevalence of psoriasis ranges from 0.09% in countries with warmer climates to 11.43% in Norway, where a colder climate prevails. The European market for psoriasis is estimated to be 15-20 Million patients.
Mr. Mordechai Bignitz, OWCP's Chairman and CEO, commented on the announcement, "We are excited to partner with Michepro Holding Ltd. The investment proceeds will be used to accelerate development of several of OWCP's products and support international marketing activities". Mr. Bignitz went on to say: "the recent activity in OWC stock has given rise to numerous investment proposals, but after reviewing the options we believe that Michepro Holding Ltd represents the best opportunity for the Company and our shareholders. Their EU business development experience and marketing expertise, as well as their enthusiasm about our future as a company are very encouraging, and it is the perfect follow-up to the agreement with signed with MedMar for the US."
Mr. Bignitz competed, "We believe the European market represents a substantial opportunity. Medical cannabis is already administrated in some countries in Europe, with several markets indicating they are on the brink of approval. Our initial focus will be the Netherlands, Czech Republic, Italy, Germany and the UK."
Commenting on his investment, Mr. Michael Brath a Director of Michepro Holding Ltd said, "OWC is the perfect match to our investment strategy; they are pioneers in the field of medical cannabis clinical research and we see incredible value in the work they are doing which is exactly what has been missing from thisMMJ market. We decided to invest and partner with them because I believe that our resources across the EU will significantly accelerate their ability to commercialize those efforts throughout that market - initially with the psoriasis treatment, and then with other therapies as they come online"
Psoriasis is an autoimmune disease that causes red, scaly patches to appear on the skin, and can be associated with other serious health conditions, including diabetes, heart disease and depression. Skin cells in patients with psoriasis grow at an abnormally fast rate, causing a buildup of lesions that tend to burn and itch. While the real cause of psoriasis is not known, genetics are believed to play a major role in its development.
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively "OWC" or the "Company" conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.
The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information, visit: http://www.owcpharma.com/
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact Information:
In Israel:
Ziv Turner, Chief Executive Officer - One World Cannabis Ltd.
Email: ziv.turner@owcpharma.com
Tel: +972-(0)3-7582659
In the United States:
Jeffrey Friedland
Email: Jfriedland@owcpharma.com
Tel: +1-(646)-450-8909
SOURCE OWC Pharmaceutical Research Corp.
Copyright © 2016 PR Newswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
New Colombia Resources Inc to Produce Infomercials to Sell All Natural 100% Organic Cannabis Based Products from Colombia to the U.S. Hispanic and Latin American Markets
Oct 21, 2016
OTC Disclosure & News Service
-
New Colombia Resources Inc to Produce Infomercials to Sell All Natural 100% Organic Cannabis Based Products from Colombia to the U.S. Hispanic and Latin American Markets
Advertising to be produced by top Hispanic infomercial company in Miami
PR Newswire
BARRANQUILLA, Colombia, October 21, 2016
BARRANQUILLA, Colombia, October 21, 2016 /PRNewswire/ --
New Colombia Resources, Inc. (OTC: NEWC) ("New Colombia or the Company" , a U.S. listed Colombian company with natural resource assets in Colombia, is pleased to announce plans to produce several infomercials targeting the U.S. Hispanic and Latin American Markets. The Company had previously engaged top infomercial producer to conduct a market survey of pain products vs. beauty products.
Doral Studios Inc. d/b/a RC Television Production has been producing English and Spanish speaking infomercials and music videos for over 15 years. They have a state of the art production studio in Doral, FL where they have produced the most successful Spanish language infomercials on the air in the U.S. and Latin America. RC Television handles every aspect of an infomercial including: concept, logo, animation, graphics, passive and aggressive CTA (Call to Action), and high definition production. They work with focus groups to determine the direction of the product or idea.
Rafael Campo, Owner of Doral Studios, has long standing relationships with the biggest Spanish language broadcasters in the world and works with telemarketing associates to handle incoming calls. New Colombia Resources' President, John Campo, and Rafael Campo are related. To view Doral Studios demos visit http://www.youtube.com/results?search_query=doral+studios
Doral Studios conducted a survey to determine what type of cannabis based product would be most accepted by their target audience. The population subject of the study included male and female professionals, makeup artists, personal trainers, corporate executives, students, housewives, and others. The age brackets were broken down every ten years, except for the first segment that was from age 25 to 40. The results of the survey will be posted next week.
Once Doral Studios and the Company determine which product they feel will have the best results, New Colombia Resources will work with their scientific advisor, Dr. Robert Melamede PhD, President Emeritus of Cannabis Science Inc. (OTC: CBIS), a world-renowned expert on the body's Endocannabinoid System, and other credible doctors to help explain to the Hispanic and Latin American why cannabis based products work.
According to published reports, the U.S. Hispanic buying power is over $ 1.5 Trillion and spends the most on consumer goods over other multi-cultural segments. "We feel our target audience will accept our "Made in Colombia" products over other cannabis products of inferior quality," stated John Campo, President of New Colombia Resources, Inc.
Products the company plans to advertise to the Hispanic market include their all natural pain relief cream http://www.sannabis.co/_p/prd2/2838276511/pro...a-caliente made with the following all natural active ingredients...
Bees Wax
Eucalyptus
Pine
Nettle
Castor Bean
Tabaco
Cannabis Sativa Flower (5 grams)
Additionally, New Colombia Resources will give updates on their cannabis based Orphan Drug Designation application with the FDA as they develop. Other companies with orphan drug business plans include OWC Pharmaceutical Research Corp. (OTC: OWCP).
To view or purchase cannabis based products from the Company's medical marijuana joint venture in Colombia, Sannabis, visit http://www.sannabis.co. Follow Sannabis on Facebook for photos and testimonials at https://www.facebook.com/sannabis.cannamedicinal
About New Colombia Resources, Inc.
New Colombia Resources, Inc. is focused on the acquisition and development of high-quality metallurgical coal properties and other available resources in the Republic of Colombia. They expect to have several revenues producing businesses including; metallurgical coal mining and rock quarry aggregates for domestic Colombian highway and railroad building projects, and medical marijuana products. The Company owns 100% of La Tabaquera metallurgical coal mine in Colombia with an estimated 15- 17 million tonnes of reserves. They have another pending acquisition for 390 ha and a solicitation contract for 184 ha metallurgical coal concession. New Colombia Resources holds a significant position in Sannabis SAS which legally produces medical marijuana products in the Republic of Colombia, visit http://www.sannabis.co. For more information on the Company visit http://www.newcolombiaresources.com.
Transportation, Logistics and Other Information
New Colombia Resources intends to sell their coal at the mine's gate unless they enter into off-take agreements. Upon proper financing, the Company plans to build or acquire river or rail loading facilities on the Magdalena River close to their mines. The coal will be trucked to these distribution centers, and then barged via the Magdalena River or by rail to terminals in Barranquilla, Santa Marta, or Cartagena for export. Initially they will use existing logistics providers while their transportation projects are being developed. After the rail projects and the "Road to the Sun" project are completed, New Colombia Resources will have one of a few metallurgical coal mines in the World with river, rail, and road access to coal export terminals on both the Atlantic and Pacific Oceans.
Forward Looking Statements
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include financing, the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations. New Colombia Resources, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Media/Company Contact:
New Colombia Resources, Inc.
John Campo
President/Chairman
+1-410-236-8200 USA
+57-318-657-0918 Colombia
jcampo@newcolombiaresources.com
SOURCE New Colombia Resources Inc.
Copyright © 2016 PR Newswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
OWC Pharmaceutical Research Corp Completes Development of Its Medical Cannabis Sublingual Tablet
Oct 20, 2016
OTC Disclosure & News Service
-
OWC Pharmaceutical Research Corp Completes Development of Its Medical Cannabis Sublingual Tablet
The Proprietary Delivery Mechanism Provides Smoke-Free Alternative For Patients Using Medical Cannabis
PR Newswire
PETACH TIKVA, Israel, October 20, 2016
PETACH TIKVA, Israel, October 20, 2016 /PRNewswire/ --
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company" , an Israeli-based developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced that it has completed the development of a proprietary, cannabinoid-enriched sublingual tablet (the "Tablet" for the administration of medical cannabis.
(Logo: http://photos.prnewswire.com/prnh/20150311/734965-b )
(Photo: http://photos.prnewswire.com/prnh/20161020/430820 )
The technology behind the Tablet is protected and provides for the ingestion of virtually any dosage of medical cannabis with a sublingual delivery mechanism, whereby the compounds are absorbed directly into the patient's blood through oral epithelial tissue. The Tablet also enables physicians to safely and accurately monitor the dosage and treatment of each individual patient, something that is essentially impossible to do for patients who administer cannabis by smoking.
The Company is working towards having the Tablet approved by the Israeli Medicinal Cannabis Unit under the Ministry of Health office for use within the country's sanctioned medical cannabis program, as well as talking with potential licensees of the technology in the United States. Longer term, management expects to establish clinical tests of the Tablet in protocols for Multiple Myeloma, Post-Traumatic Stress Disorder (PTSD), and Fibromyalgia.
Development of the Tablet was overseen by the Company's Director of Research and Regulatory Affairs, Dr. Yehuda Baruch, who established and served as the first Head of the Israeli Ministry of Health's Medical Cannabis (Marijuana) Program from 2003 through 2013. During his tenure, Dr. Baruch treated more than 15,000 patients in Israel with cannabis.
Dr. Baruch commented on the announcement, "Although smoking is the most common way of dosing medical cannabis, while serving as Head of the Israeli Ministry of Health's Medical Cannabis Program, I observed that about fifteen percent of eligible patients do not use medical cannabis because they cannot, or do not want to smoke it. What's more, smoking is not particularly effective for some conditions. We developed the tablet to facilitate the bioavailability and administration of our cannabis formulations to patients. Consistent and accurate dosing is critical to the successful treatment of any condition, and our Tablet is able to deliver that."
Ziv Turner, OWC's CEO, also commented, "We expect that there is a substantial number of eligible patients who are uncomfortable smoking cannabis for medical purposes in the United States as well as other regions, leaving a large segment of the patient population without real access to treatment. We believe our tablet is a preferable administrative method for those, and many other patients, and will make a real difference in the way cannabis is administered."
Mr. Turner went on to say, "We are already in discussion with the Ministry of Health here in Israel, and we have been solicited by a number of licensee candidates looking to bring the technology to the States. Of course we will have to pursue the US market on a state by state basis, as regulations allow."
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively "OWC" or the "Company" conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.
The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information, visit: http://www.owcpharma.com/
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact Information:
In Israel:
Ziv Turner, Chief Executive Officer - One World Cannabis Ltd.
Email: ziv.turner@owcpharma.com
Tel: +972-(0)54-5500450
SOURCE OWC Pharmaceutical Research Corp.
Copyright © 2016 PR Newswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
OWC Pharmaceutical Research Corp to Initiate Efficacy Testing on its Cannabinoid-Infused Cream for Treatment of Psoriasis
Oct 11, 2016
OTC Disclosure & News Service
-
OWC Pharmaceutical Research Corp to Initiate Efficacy Testing on its Cannabinoid-Infused Cream for Treatment of Psoriasis
Company Anticipates Product Launch In Second Quarter 2017
PR Newswire
PETACH TIKVA, Israel, October 11, 2016
PETACH TIKVA, Israel, October 11, 2016 /PRNewswire/ --
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company" , an Israeli-based developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced it is starting the final phase for testing the efficacy of its own developed topical crème compound for the treatment of psoriasis and related skin conditions.
(Logo: http://photos.prnewswire.com/prnh/20150311/734965-a )
(Logo: http://photos.prnewswire.com/prnh/20150311/734965-b )
The Company's recently completed Challenge Testing for the topical crème, successfully demonstrated the product's robustness against microbiological contamination, stability, and provided a preliminary safety assessment. This next phase of Safety testing protocol was designed to corroborate that the cream is safe for application to the skin. This will be demonstrated by giving a highly concentrated topical crème formulation to healthy patients within a hospital controlled environment. The safety phase will start upon receiving the Institutional Review Board (IRB) approval by the national IRB committee which is expected to be assembled in November 2016.
OWC is also preparing to initiate in parallel Efficacy Testing using MatTek Corporation patented EpiDerm™ system, an in-vitro testing technology for dermal toxicologists. This protocol will seek to prove the effectiveness of the formulation in treating psoriasis on human skin tissue. The tests will be conducted at an approved international lab of Dead Sea & Arava Science Center under the auspices of the Ben-Gurion University of the Negev (http://www.adssc.org/ ).
Dr. Yehuda Baruch, the Company's Director of Research and Regulatory Affairs, commented on the announcement, "Psoriasis is an affliction of the immune system resulting in sub-dermal infection that can be painful and uncomfortable. Cannabis is believed to provide relief from some infections and skin conditions, and it is a central ingredient in our topical crème formulation. Our preliminary studies indicate the formulation does provide relief of these symptoms, and we are confident that these studies will corroborate those results."
Ziv Turner, OWC's CEO, went on to say, "We are excited to begin this last phase of testing so that we can finally make this product available for all psoriasis sufferers. We hope to start sales and marketing both in Israel the US in the second quarter of 2017, and have already been in contact with a number of representatives who have expressed interest in manufacturing and distributing the crème in their state. Of course, we also continue our work on multiple myeloma and other conditions, so I am hopeful that this is just the first of many products that will follow."
Psoriasis is an autoimmune disease that causes red, scaly patches to appear on the skin, and can be associated with other serious health conditions, including diabetes, heart disease and depression. Skin cells in patients with psoriasis grow at an abnormally fast rate, causing a buildup of lesions that tend to burn and itch. While the real cause of psoriasis is not known, genetics are believed to play a major role in its development. According to the National Psoriasis Foundation, psoriasis affects 7.5 million people in the United States.
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively "OWC" or the "Company" conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.
The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information, visit: http://www.owcpharma.com/
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact Information:
In Israel:
Ziv Turner, Chief Executive Officer - One World Cannabis Ltd.
Email: ziv.turner@owcpharma.com
Tel: +972-(0)3-7582659
SOURCE OWC Pharmaceutical Research Corp.
Copyright © 2016 PR Newswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
OWC Pharmaceutical Research Corp Signs Agreement With US Partner for Funding in Advance of Future Royalties
Sep 30, 2016
OTC Disclosure & News Service
-
OWC Pharmaceutical Research Corp Signs Agreement With US Partner for Funding in Advance of Future Royalties
Initial Focus Will Be Commercialization Of Company's Topical Psoriasis Treatment
PR Newswire
PETACH TIKVA, Israel, September 30, 2016
PETACH TIKVA, Israel, September 30, 2016 /PRNewswire/ --
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company" , an Israeli-based developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced it signed an agreement for $300,000 with Medmar LLC ("Medmar" .
(Logo: http://photos.prnewswire.com/prnh/20150311/734965-a )
(Logo: http://photos.prnewswire.com/prnh/20150311/734965-b )
According to the terms of the agreement:
The funds will be allocated to complete the development of the Company's proprietary psoriasis cream;
Medmar will have exclusive right to manufacture, produce, publicize, promote and market OWC's Licensed Products in any state in the U.S;
The loan is non-interest bearing and will be repaid from royalties generated by the sale of OWC licensed products.
Commenting on his investment, Steve Weinstein, CEO of Medmar said, "Medmar has been anxious to advance cannabis as medicine, however US regulation makes it very difficult for companies here to actively pursue any type of development in the sector; fortunately, the environment in Israel is more favorable to the industry."
Mr. Weinstein went on to say, "We learned about OWC as they are one of only a handful of companies taking a true clinical approach to the research and development of medical cannabis, and this was important to us. Once we saw the preliminary results for their clinical studies, particularly in the field of psoriasis, we decided to make an investment and partner with them."
Mordechai Bignitz, OWC's Chairman and CEO, also commented on the announcement, "As we continue to make progress in our clinical trials for multiple myeloma, psoriasis and fibromyalgia, we are excited to partner with MedMar as we prepare to bring products to market. Their confidence in the potential for the commercialization of our research is clearly evident in the terms of this agreement."
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively "OWC" or the "Company" conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.
The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information, visit: http://www.owcpharma.com/
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact Information:
In Israel:
Ziv Turner, Chief Executive Officer - One World Cannabis Ltd.
Email: ziv.turner@owcpharma.com
Tel: +972-(0)3-7582659
In the United States:
Jeffrey Friedland
Email: Jfriedland@owcpharma.com
Tel: +1-646-450-8909
SOURCE OWC Pharmaceutical Research Corp.
Copyright © 2016 PR Newswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
OWC Pharmaceuticals Corp to Present at Israeli Advanced Technology Industry's BioMed Conference
Apr 26, 2016
OTC Disclosure & News Service
-
OWC Pharmaceuticals Corp to Present at Israeli Advanced Technology Industry's BioMed Conference
Selected To Present at the Start-ups Hall Booth #80
PR Newswire
PETACH TIKVA, Israel, April 26, 2016
PETACH TIKVA, Israel, April 26, 2016 /PRNewswire/ --
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company" , an Israeli-based developer of cannabinoid-based therapies targeting a variety of different indications, today announced that it was selected to present at the 2016 Israeli Advanced Technology Industries (IATI) BioMed Conference (the "Conference" .
(Logo: http://photos.prnewswire.com/prnh/20150311/734965-a )
(Logo: http://photos.prnewswire.com/prnh/20150311/734965-b )
The Conference is a part of Israel's 15th National Life Sciences and Technology Week, and is being held May 24th to 26th at the David Intercontinental Hotel in Tel Aviv, Israel. The Company is currently scheduled to present at Booth #80 on the 24th .
The Biomed conference is the preeminent event for the Israeli life sciences industry, attracting leading members of the healthcare industry from around the globe. It comprises group discussions, panel presentations, product demonstrations and networking opportunities, all designed to encourage business collaborations. Attendees are able to experience firsthand the entrepreneurial spirit which is a basis of Israel's vibrant life sciences community. Prior conferences have hosted over 6,000 industry senior executives, scientists, and engineers, including approximately 1,000 participants from over 45 countries and in excess of 4,500 one-on-one meetings.
Ziv Turner, OWC Israel CEO stated, "We are so proud to have been selected by IATI to participate in BioMed. This is the biggest and most established annual meeting of the Israeli life science industry. The conference attracts investors and companies from around the world who are looking for innovation and ground breaking technology, providing us with the opportunity to meet one on one with potential investors, strategic partners and collaborators."
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively "OWC" or the "Company" conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. The Company is a wholly owned subsidiary of OWC Pharmaceutical Research Corp. (OTCQB: OWCP). For more information, visit: http://www.owcpharma.com/
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact Information:
In Israel:
Ziv Turner, Chief Executive Officer - One World Cannabis Ltd.
Email: ziv.turner@owcpharma.com
Tel: +972-(0)3-7582659
In the United States:
Jeffrey Friedland
Email: Jfriedland@owcpharma.com
Tel: +1-(646)-450-8909
SOURCE OWC Pharmaceutical Research Corp.
Copyright © 2016 PR Newswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
Last updated 01/07/2017 - 0.1845
CFN Media Exclusive Interview with Jeffrey Friedland, Advisory Board Member for OWC Pharmaceutical Research
Jan 04, 2017
OTC Disclosure & News Service
-
CFN Media Exclusive Interview with Jeffrey Friedland, Advisory Board Member for OWC Pharmaceutical Research
SEATTLE, WA--(Marketwired - Jan 4, 2017) - CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an exclusive interview with Jeffrey Friedland, CEO of Intiva Inc. and member of the Advisory Board for OWC Pharmaceutical Research Corp. (OTCQB: OWCP).
Mr. Friedland, author of the book Marijuana: The World's Most Understood Plant, discusses the legal cannabis industry in general, the reasons why his company decided to invest in OWC Pharmaceutical Research, and the outlook for both OWC and the pharmaceutical side of the emerging industry moving forward.
Please follow the link to view the interview: http://www.cannabisfn.com/cfnvideo/?id=Q8qC1EFo
Learn how to become a CFN Media featured company, brand or entrepreneur: http://www.cannabisfn.com/become-featured-company/
Download the CFN Media iOS mobile app to access the world of cannabis from your smart phone: https://itunes.apple.com/us/app/cannabisfn/id...1&mt=8
Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively "OWC" or the "Company"
conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information, visit: http://www.owcpharma.com/
Disclaimer:
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and CannabisFN.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.
Contact:
Frank Lane
206 369 7050
flane@cannabisfn.com
Copyright © 2017 Marketwired. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
OWC Pharmaceutical Research Advisory Board Member to Participate in the First Bloomberg Intelligence Sponsored Cannabis Event
Nov 18, 2016
OTC Disclosure & News Service
-
OWC Pharmaceutical Research Advisory Board Member to Participate in the First Bloomberg Intelligence Sponsored Cannabis Event
Bloomberg's "Cannabis Trends & Legalization Implications" Will be Held Monday, November 21st in New York
PR Newswire
PETACH TIKVA, Israel, November 18, 2016
PETACH TIKVA, Israel, November 18, 2016 /PRNewswire/ --
PETACH TIKVA, Israel, November 18, 2016: OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company"
, a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced that Jeffrey Friedland, a member of the Company's Advisory Board, will be participating in Bloomberg Intelligence's first cannabis-related event; Cannabis Trends & Legalization Implications. (Logo: http://photos.prnewswire.com/prnh/20150311/734965-a )
(Logo: http://photos.prnewswire.com/prnh/20150311/734965-b )
Cannabis Trends & Legalization Implications will be held Monday, November 21st in New York City, and will explore the most important legal, medical and financial developments and issues associated with America's marijuana industry. The session will start with a panel of key players in the space, dissecting the implications and opportunities associated with cannabis decriminalization across the United States. It will be moderated by Kenneth Shea, Senior Consumer Products Analyst of Bloomberg Intelligence.
It is anticipated that Mr. Friedland, who is also the author of Marijuana: The World's Most Misunderstood Plant, will have the opportunity to highlight to event attendees the progress that OWC has made with its medical cannabis research in Israel, and the positive impact that OWC and other Israeli companies are having on state-licensed U.S. growers and extractors.
When asked about his participation in the Bloomberg event, Mr. Friedland stated, "I've been involved in the legal cannabis industry for several years now; including as the CEO of INTIVA Inc., an investor and operator of businesses in the global cannabis market. I view the cannabis industry as an emerging global market with several sectors, including medical, recreational, services and equipment, each with their own unique opportunities for investors and entrepreneurs. While many industry participants are very speculative, as the legalization of both recreational and medical cannabis spreads, I've concluded that the real money will be made by companies that not only harness science to differentiate their products, but are also able to get those products into the marketplace."
Friedland went on to say, "There are many cannabis companies that are publicly-traded, from GW Pharmaceuticals (GWPH) to smaller public companies such as OWC, which Intiva invested in during the summer of 2014 when OWC's research into the effects of cannabis on conditions including multiple myeloma, psoriasis and PTSD caught our attention; I joined the Company's advisory board earlier this year. OWC's recent announcements of partnerships to bring its cannabis-based topical psoriasis product to licensed markets in the US and EU are significant events for the Company, and indicate positive directions for the execution of their business model."
Subject to his schedule, Mr. Friedland may be available to meet privately with OWC shareholders to discuss his view of OWC's future.
About Bloomberg Intelligence
Bloomberg Intelligence is the research arm of Bloomberg L.P. It provides in-depth analysis and data sets on industries, companies and credit, government economic and litigation factors that impact decision making.
About Jeffrey Friedland
Jeffrey Friedland is an emerging market pioneer -- his firm, Friedland Global Capital, was one of the first American investment banks to establish a presence in China -- and he can now be found on the forefront of the cannabis movement. In his book, Marijuana: The World's Most Misunderstood Plant guides the reader through the plant's rich, and sometimes scandalous history, explains how and why cannabis affects us, describes the methods of breeding, cultivating and processing that plant, and perhaps most importantly, provides an overview of the most recent research into its potential of cannabinoid-based medicine.
Mr. Friedland was an owner of two retail cannabis stores in Colorado in the mountain resort towns of Breckenridge and Crested Butte, and a cannabis cultivation facility located south of Steamboat Springs. These businesses were featured in CNN's 2015 reality series, High Profits. He is also CEO of INTIVA Inc., a multi-faceted life sciences company in the worldwide legal cannabis industry that has established businesses and made investments in the cannabis industry in California, Colorado, Canada and Israel.
Mr. Friedland is also CEO of the financial services firm Friedland Global Capital, which provides corporate finance and strategic advisory services to entrepreneurial companies in emerging markets. He has been the CEO of a Nasdaq-listed company, a member of the board of directors and chairman of the audit committee of a New York Stock Exchange-listed company, and the chairman of the supervisory board of a company listed on the Regulated Market of the Frankfurt Stock Exchange. Mr. Friedland has been featured, interviewed or quoted in numerous publications including the Wall Street Journal, USA Today, The South China Morning Post (Hong Kong), NBC.com, Forbes, CNBC and its predecessor, Financial News Network, Bloomberg Information Radio, and Bloomberg TV. This is the second book he has written. His first book, All Roads Lead to China: An Investor Road Map to the World's Fastest Growing Economy, was published in 2014.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact Information:
In Israel:
Ziv Turner, Chief Executive Officer - One World Cannabis Ltd.
Email: ziv.turner@owcpharma.com
Tel: +972-(0)3-7582659
SOURCE OWC Pharmaceutical Research Corp.
Copyright © 2016 PR Newswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
OWC Pharmaceutical Research Corp to Submit Psoriasis Topical Cream IRB Safety Protocol to the Israeli National IRB ("Helsinki"
Committee Nov 15, 2016
OTC Disclosure & News Service
-
OWC Pharmaceutical Research Corp to Submit Psoriasis Topical Cream IRB Safety Protocol to the Israeli National IRB ("Helsinki"
Committee Final IRB ("Institutional Review Board"
for safety study PR Newswire
PETACH TIKVA, Israel, November 15, 2016
PETACH TIKVA, Israel, November 15, 2016 /PRNewswire/ --
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWCP" or the "Company"
, thorough its Israeli based fully owned subsidiary, a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced it is submitting the final Psoriasis IRB safety protocol for the Israeli national IRB committee at the Health Minister office. (Logo: http://photos.prnewswire.com/prnh/20150311/734965-b )
(Photo: http://photos.prnewswire.com/prnh/20161115/439488 )
The IRB protocol was first approved by the hospital which will perform the safety study and after obtaining its approval the IRB protocol is being submitted for approval to the national IRB committee. The national IRB committee is scheduled to ensemble at the beginning of December 2016.
Upon the expected approval of the safety protocol by the national committee, the company will immediately engage with the study which will last approximately 12 weeks.
Results are expected by the end of March 2016 and upon reaching satisfactory results the company intends to start production, marketing and sales in the US and EU in parallel to local IL efforts.
The Safety study is designed to test multiple escalating doses to determine the safety and tolerability of the medical grade cannabis cream on healthy volunteers. The psoriasis topical crème infused with active cannabinoids is a unique delivery-system product of OWC designed to be used for skin diseases, where the first application will be tested for safety and efficacy for Psoriasis. The efficacy studies have already been started and results are expected by the end of Jan 2017.
Psoriasis is an autoimmune disease that causes red, scaly patches to appear on the skin, and can be associated with other serious health conditions, including diabetes, heart disease and depression. The World Health Organization's 2016 Global Report on Psoriasis states that psoriasis is a serious global problem affecting at least 100 million individuals worldwide with estimated 8 million patients in the US. The report indicates the prevalence of psoriasis ranges from 0.09% in countries with warmer climates to 11.43% in Norway, where a colder climate prevails. The European market for psoriasis is estimated to be 15-20 Million patients.
Dr. Yehuda Baruch, the Company's CSO & Director of Research and Regulatory Affairs said, "Best to my knowledge this is the first Cannabis safety study that was submitted to the Israeli IRB national committee to be performed on healthy volunteers. I am also not aware of any other cannabis infused topical crème that was tested for safety, efficacy and bio-availability with approved IRB. That makes our products unique and valuable which matches exactly the company's vision and targets to develop approved, safe and effective active-cannabinoids products for medical treatments."
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively "OWC" or the "Company"
conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information, visit: http://www.owcpharma.com/
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact Information:
In Israel:
Ziv Turner, Chief Executive Officer - One World Cannabis Ltd.
Email: ziv.turner@owcpharma.com
Tel: +972-(0)3-7582659
In the United States:
Jeffrey Friedland
Email: Jfriedland@owcpharma.com
Tel: +1-(646)-450-8909
SOURCE OWC Pharmaceutical Research Corp.
Copyright © 2016 PR Newswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
OWC Pharmaceutical Corporation Advisory Board Member, Jeffrey Friedland, Comments on the Election and the Possible Impact on the U.S. Cannabis Market
Nov 07, 2016
OTC Disclosure & News Service
-
OWC Pharmaceutical Corporation Advisory Board Member, Jeffrey Friedland, Comments on the Election and the Possible Impact on the U.S. Cannabis Market
Mr. Friedland Comments Included His Thoughts On The Potential For Benefit To The Company
PR Newswire
PETACH TIKVA, Israel, November 7, 2016
PETACH TIKVA, Israel, November 7, 2016 /PRNewswire/ --
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), through its Israeli based fully owned subsidiary, (collectively "OWC" or the "Company"
a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, was featured in the comments of its Advisory Board member, Jeffrey Friedland. In addition to serving on the Company's Advisory Board, Mr. Friedland is the Chief Executive Officer of Intiva Inc., author of Marijuana: The World's Most Misunderstood Plant, and frequent keynote speaker for the cannabis industry. (Logo: http://photos.prnewswire.com/prnh/20150311/734965-a )
(Logo: http://photos.prnewswire.com/prnh/20150311/734965-b )
Recently, Mr. Friedland commented on the pending election and the possible effects on the future of the cannabis industry, "Many entrepreneurs and investors have expressed their concerns to me regarding the outcome of Tuesday's U.S. presidential election, specifically whether the winner will have a positive or negative impact on the cannabis industry. Both Hillary Clinton and Donald Trump have stated that they will support the medical use of cannabis."
Mr. Friedland went on to say, "Regardless of the outcome of Tuesday's vote, I see no immediate change in the existing system of allowing state-licensed medical cannabis businesses, nor do I see any immediate change in the rescheduling of cannabis under the Controlled Substances Act…..What is more significant to the U.S. cannabis industry is Tuesday's outcome of voting in California and Nevada, where adult recreational use of cannabis is on the ballot. I'm expecting voters in both states to approve recreational cannabis."
Regarding Intiva's investment in OWC, Mr. Friedland had this to say, "The decision to invest in OWC during the summer of 2014 came after spending some time in Israel, where I concluded that the real money in the cannabis industry will be made by companies who create 'real pharmaceuticals based on real science.' I was impressed with OWC's management team; Dr. Yehuda Baruch, the Company's director of research, was the former head of Israel's medical cannabis program. I also found intriguing the early-stage research OWC had underway regarding trials of their proprietary cannabis-based formulations for the treatment of multiple myeloma and other conditions."
As for the potential effect of the election on OWC, Mr. Friedland added that if, as he expected, California and Nevada approved recreational cannabis, the Company had "plenty to gain from Tuesday's vote in the U.S……as OWC Pharmaceutical Research recently announced that it has entered into a U.S. license agreement with a Maryland-based company to bring its topical psoriasis cream to state-licensed businesses in the U.S. market….and the establishment of recreational cannabis businesses in California and Nevada would significantly increase the availability of medical cannabis for patients in those states.
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively "OWC" or the "Company"
conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information, visit: http://www.owcpharma.com/
About Jeffrey Friedland
Jeffrey Friedland is an emerging market pioneer -- his firm, Friedland Global Capital, was one of the first American investment banks to establish a presence in China -- and he can now be found on the forefront of the cannabis movement. In his book, Marijuana: The World's Most Misunderstood Plant guides the reader through the plant's rich, and sometimes scandalous history, explains how and why cannabis affects us, describes the methods of breeding, cultivating and processing that plant, and perhaps most importantly, gives an overview of the most recent research into its potential within the word of medicine.
Mr. Friedland was an owner of two retail cannabis stores in Colorado in the mountain resort towns of Breckenridge and Crested Butte, and a cannabis cultivation facility located south of Steamboat Springs, which were featured in CNN's 2015 reality series, High Profits. He is also CEO of INTIVA Inc., a multi-faceted life sciences company in the worldwide legal cannabis industry. INTIVA has established operating businesses and made venture investments in the cannabis industry in California, Colorado, Canada and Israel.
Mr. Friedland is also CEO of the financial services firm Friedland Global Capital, which provides corporate finance and strategic advisory services to entrepreneurial companies in emerging markets. He has been the CEO of a Nasdaq-listed company, a member of the board of directors and chairman of the audit committee of a New York Stock Exchange-listed company, and the chairman of the supervisory board of a company listed on the Regulated Market of the Frankfurt Stock Exchange. Mr. Friedland has been featured, interviewed or quoted in numerous publications including the Wall Street Journal, USA Today, The South China Morning Post (Hong Kong), NBC.com, Forbes, CNBC and its predecessor, Financial News Network, Bloomberg Information Radio, and Bloomberg TV. This is the second book he has written. All Roads Lead to China: An Investor Road Map to the World's Fastest Growing Economy was published in 2014.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact Information:
In Israel
Ziv Turner, Chief Executive Officer - One World Cannabis Ltd.
Email: ziv.turner@owcpharma.com
Tel: +972(0)3-7582659
SOURCE OWC Pharmaceutical Research Corp.
Copyright © 2016 PR Newswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
OWC Pharmaceutical Research Corp Signs Investment and Joint Venture with Michepro Holdings Ltd
Nov 03, 2016
OTC Disclosure & News Service
-
OWC Pharmaceutical Research Corp Signs Investment and Joint Venture with Michepro Holdings Ltd
Initial Focus Will Be Commercialization of Company's Topical Psoriasis Treatment in the European Union
PR Newswire
PETACH TIKVA, Israel, November 3, 2016
PETACH TIKVA, Israel, November 3, 2016 /PRNewswire/ --
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWCP" or the "Company"
, through its Israeli based fully owned subsidiary, a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced it has inked agreement for a combined JV & Private Placement of $300,000 with Michepro Holding Ltd a private family investment company organized under the laws of the state of Cyprus ("The Investor\ partner " . (Logo: http://photos.prnewswire.com/prnh/20150311/734965-a )
(Photo: http://photos.prnewswire.com/prnh/20161103/435811 )
The Investor will be issued with 2,307,692 restricted shares of the Company's common stock (a price of $0.13 per share) with additional warrants to purchase 761,538 restricted shares at an exercise price of $0.25 per share for a period of 24 months, and additional warrants for 761,538 restricted shares at an exercise price of $0.40 per share for a period of 36 months. In addition to the investment, the parties will establish a joint venture, 75% to OWCP and 25% to Michepro Holding Ltd to promote, sell, market and distribute the Company's potential products in Europe, initially with the psoriasis treatment, to be followed with company's other therapies as they become available."
The World Health Organization's 2016 Global Report on Psoriasis states that psoriasis is a serious global problem affecting at least 100 million individuals worldwide. The report indicates the prevalence of psoriasis ranges from 0.09% in countries with warmer climates to 11.43% in Norway, where a colder climate prevails. The European market for psoriasis is estimated to be 15-20 Million patients.
Mr. Mordechai Bignitz, OWCP's Chairman and CEO, commented on the announcement, "We are excited to partner with Michepro Holding Ltd. The investment proceeds will be used to accelerate development of several of OWCP's products and support international marketing activities". Mr. Bignitz went on to say: "the recent activity in OWC stock has given rise to numerous investment proposals, but after reviewing the options we believe that Michepro Holding Ltd represents the best opportunity for the Company and our shareholders. Their EU business development experience and marketing expertise, as well as their enthusiasm about our future as a company are very encouraging, and it is the perfect follow-up to the agreement with signed with MedMar for the US."
Mr. Bignitz competed, "We believe the European market represents a substantial opportunity. Medical cannabis is already administrated in some countries in Europe, with several markets indicating they are on the brink of approval. Our initial focus will be the Netherlands, Czech Republic, Italy, Germany and the UK."
Commenting on his investment, Mr. Michael Brath a Director of Michepro Holding Ltd said, "OWC is the perfect match to our investment strategy; they are pioneers in the field of medical cannabis clinical research and we see incredible value in the work they are doing which is exactly what has been missing from thisMMJ market. We decided to invest and partner with them because I believe that our resources across the EU will significantly accelerate their ability to commercialize those efforts throughout that market - initially with the psoriasis treatment, and then with other therapies as they come online"
Psoriasis is an autoimmune disease that causes red, scaly patches to appear on the skin, and can be associated with other serious health conditions, including diabetes, heart disease and depression. Skin cells in patients with psoriasis grow at an abnormally fast rate, causing a buildup of lesions that tend to burn and itch. While the real cause of psoriasis is not known, genetics are believed to play a major role in its development.
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively "OWC" or the "Company"
conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information, visit: http://www.owcpharma.com/
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact Information:
In Israel:
Ziv Turner, Chief Executive Officer - One World Cannabis Ltd.
Email: ziv.turner@owcpharma.com
Tel: +972-(0)3-7582659
In the United States:
Jeffrey Friedland
Email: Jfriedland@owcpharma.com
Tel: +1-(646)-450-8909
SOURCE OWC Pharmaceutical Research Corp.
Copyright © 2016 PR Newswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
New Colombia Resources Inc to Produce Infomercials to Sell All Natural 100% Organic Cannabis Based Products from Colombia to the U.S. Hispanic and Latin American Markets
Oct 21, 2016
OTC Disclosure & News Service
-
New Colombia Resources Inc to Produce Infomercials to Sell All Natural 100% Organic Cannabis Based Products from Colombia to the U.S. Hispanic and Latin American Markets
Advertising to be produced by top Hispanic infomercial company in Miami
PR Newswire
BARRANQUILLA, Colombia, October 21, 2016
BARRANQUILLA, Colombia, October 21, 2016 /PRNewswire/ --
New Colombia Resources, Inc. (OTC: NEWC) ("New Colombia or the Company"
, a U.S. listed Colombian company with natural resource assets in Colombia, is pleased to announce plans to produce several infomercials targeting the U.S. Hispanic and Latin American Markets. The Company had previously engaged top infomercial producer to conduct a market survey of pain products vs. beauty products. Doral Studios Inc. d/b/a RC Television Production has been producing English and Spanish speaking infomercials and music videos for over 15 years. They have a state of the art production studio in Doral, FL where they have produced the most successful Spanish language infomercials on the air in the U.S. and Latin America. RC Television handles every aspect of an infomercial including: concept, logo, animation, graphics, passive and aggressive CTA (Call to Action), and high definition production. They work with focus groups to determine the direction of the product or idea.
Rafael Campo, Owner of Doral Studios, has long standing relationships with the biggest Spanish language broadcasters in the world and works with telemarketing associates to handle incoming calls. New Colombia Resources' President, John Campo, and Rafael Campo are related. To view Doral Studios demos visit http://www.youtube.com/results?search_query=doral+studios
Doral Studios conducted a survey to determine what type of cannabis based product would be most accepted by their target audience. The population subject of the study included male and female professionals, makeup artists, personal trainers, corporate executives, students, housewives, and others. The age brackets were broken down every ten years, except for the first segment that was from age 25 to 40. The results of the survey will be posted next week.
Once Doral Studios and the Company determine which product they feel will have the best results, New Colombia Resources will work with their scientific advisor, Dr. Robert Melamede PhD, President Emeritus of Cannabis Science Inc. (OTC: CBIS), a world-renowned expert on the body's Endocannabinoid System, and other credible doctors to help explain to the Hispanic and Latin American why cannabis based products work.
According to published reports, the U.S. Hispanic buying power is over $ 1.5 Trillion and spends the most on consumer goods over other multi-cultural segments. "We feel our target audience will accept our "Made in Colombia" products over other cannabis products of inferior quality," stated John Campo, President of New Colombia Resources, Inc.
Products the company plans to advertise to the Hispanic market include their all natural pain relief cream http://www.sannabis.co/_p/prd2/2838276511/pro...a-caliente made with the following all natural active ingredients...
Bees Wax
Eucalyptus
Pine
Nettle
Castor Bean
Tabaco
Cannabis Sativa Flower (5 grams)
Additionally, New Colombia Resources will give updates on their cannabis based Orphan Drug Designation application with the FDA as they develop. Other companies with orphan drug business plans include OWC Pharmaceutical Research Corp. (OTC: OWCP).
To view or purchase cannabis based products from the Company's medical marijuana joint venture in Colombia, Sannabis, visit http://www.sannabis.co. Follow Sannabis on Facebook for photos and testimonials at https://www.facebook.com/sannabis.cannamedicinal
About New Colombia Resources, Inc.
New Colombia Resources, Inc. is focused on the acquisition and development of high-quality metallurgical coal properties and other available resources in the Republic of Colombia. They expect to have several revenues producing businesses including; metallurgical coal mining and rock quarry aggregates for domestic Colombian highway and railroad building projects, and medical marijuana products. The Company owns 100% of La Tabaquera metallurgical coal mine in Colombia with an estimated 15- 17 million tonnes of reserves. They have another pending acquisition for 390 ha and a solicitation contract for 184 ha metallurgical coal concession. New Colombia Resources holds a significant position in Sannabis SAS which legally produces medical marijuana products in the Republic of Colombia, visit http://www.sannabis.co. For more information on the Company visit http://www.newcolombiaresources.com.
Transportation, Logistics and Other Information
New Colombia Resources intends to sell their coal at the mine's gate unless they enter into off-take agreements. Upon proper financing, the Company plans to build or acquire river or rail loading facilities on the Magdalena River close to their mines. The coal will be trucked to these distribution centers, and then barged via the Magdalena River or by rail to terminals in Barranquilla, Santa Marta, or Cartagena for export. Initially they will use existing logistics providers while their transportation projects are being developed. After the rail projects and the "Road to the Sun" project are completed, New Colombia Resources will have one of a few metallurgical coal mines in the World with river, rail, and road access to coal export terminals on both the Atlantic and Pacific Oceans.
Forward Looking Statements
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include financing, the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations. New Colombia Resources, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Media/Company Contact:
New Colombia Resources, Inc.
John Campo
President/Chairman
+1-410-236-8200 USA
+57-318-657-0918 Colombia
jcampo@newcolombiaresources.com
SOURCE New Colombia Resources Inc.
Copyright © 2016 PR Newswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
OWC Pharmaceutical Research Corp Completes Development of Its Medical Cannabis Sublingual Tablet
Oct 20, 2016
OTC Disclosure & News Service
-
OWC Pharmaceutical Research Corp Completes Development of Its Medical Cannabis Sublingual Tablet
The Proprietary Delivery Mechanism Provides Smoke-Free Alternative For Patients Using Medical Cannabis
PR Newswire
PETACH TIKVA, Israel, October 20, 2016
PETACH TIKVA, Israel, October 20, 2016 /PRNewswire/ --
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company"
, an Israeli-based developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced that it has completed the development of a proprietary, cannabinoid-enriched sublingual tablet (the "Tablet" for the administration of medical cannabis. (Logo: http://photos.prnewswire.com/prnh/20150311/734965-b )
(Photo: http://photos.prnewswire.com/prnh/20161020/430820 )
The technology behind the Tablet is protected and provides for the ingestion of virtually any dosage of medical cannabis with a sublingual delivery mechanism, whereby the compounds are absorbed directly into the patient's blood through oral epithelial tissue. The Tablet also enables physicians to safely and accurately monitor the dosage and treatment of each individual patient, something that is essentially impossible to do for patients who administer cannabis by smoking.
The Company is working towards having the Tablet approved by the Israeli Medicinal Cannabis Unit under the Ministry of Health office for use within the country's sanctioned medical cannabis program, as well as talking with potential licensees of the technology in the United States. Longer term, management expects to establish clinical tests of the Tablet in protocols for Multiple Myeloma, Post-Traumatic Stress Disorder (PTSD), and Fibromyalgia.
Development of the Tablet was overseen by the Company's Director of Research and Regulatory Affairs, Dr. Yehuda Baruch, who established and served as the first Head of the Israeli Ministry of Health's Medical Cannabis (Marijuana) Program from 2003 through 2013. During his tenure, Dr. Baruch treated more than 15,000 patients in Israel with cannabis.
Dr. Baruch commented on the announcement, "Although smoking is the most common way of dosing medical cannabis, while serving as Head of the Israeli Ministry of Health's Medical Cannabis Program, I observed that about fifteen percent of eligible patients do not use medical cannabis because they cannot, or do not want to smoke it. What's more, smoking is not particularly effective for some conditions. We developed the tablet to facilitate the bioavailability and administration of our cannabis formulations to patients. Consistent and accurate dosing is critical to the successful treatment of any condition, and our Tablet is able to deliver that."
Ziv Turner, OWC's CEO, also commented, "We expect that there is a substantial number of eligible patients who are uncomfortable smoking cannabis for medical purposes in the United States as well as other regions, leaving a large segment of the patient population without real access to treatment. We believe our tablet is a preferable administrative method for those, and many other patients, and will make a real difference in the way cannabis is administered."
Mr. Turner went on to say, "We are already in discussion with the Ministry of Health here in Israel, and we have been solicited by a number of licensee candidates looking to bring the technology to the States. Of course we will have to pursue the US market on a state by state basis, as regulations allow."
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively "OWC" or the "Company"
conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information, visit: http://www.owcpharma.com/
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact Information:
In Israel:
Ziv Turner, Chief Executive Officer - One World Cannabis Ltd.
Email: ziv.turner@owcpharma.com
Tel: +972-(0)54-5500450
SOURCE OWC Pharmaceutical Research Corp.
Copyright © 2016 PR Newswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
OWC Pharmaceutical Research Corp to Initiate Efficacy Testing on its Cannabinoid-Infused Cream for Treatment of Psoriasis
Oct 11, 2016
OTC Disclosure & News Service
-
OWC Pharmaceutical Research Corp to Initiate Efficacy Testing on its Cannabinoid-Infused Cream for Treatment of Psoriasis
Company Anticipates Product Launch In Second Quarter 2017
PR Newswire
PETACH TIKVA, Israel, October 11, 2016
PETACH TIKVA, Israel, October 11, 2016 /PRNewswire/ --
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company"
, an Israeli-based developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced it is starting the final phase for testing the efficacy of its own developed topical crème compound for the treatment of psoriasis and related skin conditions. (Logo: http://photos.prnewswire.com/prnh/20150311/734965-a )
(Logo: http://photos.prnewswire.com/prnh/20150311/734965-b )
The Company's recently completed Challenge Testing for the topical crème, successfully demonstrated the product's robustness against microbiological contamination, stability, and provided a preliminary safety assessment. This next phase of Safety testing protocol was designed to corroborate that the cream is safe for application to the skin. This will be demonstrated by giving a highly concentrated topical crème formulation to healthy patients within a hospital controlled environment. The safety phase will start upon receiving the Institutional Review Board (IRB) approval by the national IRB committee which is expected to be assembled in November 2016.
OWC is also preparing to initiate in parallel Efficacy Testing using MatTek Corporation patented EpiDerm™ system, an in-vitro testing technology for dermal toxicologists. This protocol will seek to prove the effectiveness of the formulation in treating psoriasis on human skin tissue. The tests will be conducted at an approved international lab of Dead Sea & Arava Science Center under the auspices of the Ben-Gurion University of the Negev (http://www.adssc.org/ ).
Dr. Yehuda Baruch, the Company's Director of Research and Regulatory Affairs, commented on the announcement, "Psoriasis is an affliction of the immune system resulting in sub-dermal infection that can be painful and uncomfortable. Cannabis is believed to provide relief from some infections and skin conditions, and it is a central ingredient in our topical crème formulation. Our preliminary studies indicate the formulation does provide relief of these symptoms, and we are confident that these studies will corroborate those results."
Ziv Turner, OWC's CEO, went on to say, "We are excited to begin this last phase of testing so that we can finally make this product available for all psoriasis sufferers. We hope to start sales and marketing both in Israel the US in the second quarter of 2017, and have already been in contact with a number of representatives who have expressed interest in manufacturing and distributing the crème in their state. Of course, we also continue our work on multiple myeloma and other conditions, so I am hopeful that this is just the first of many products that will follow."
Psoriasis is an autoimmune disease that causes red, scaly patches to appear on the skin, and can be associated with other serious health conditions, including diabetes, heart disease and depression. Skin cells in patients with psoriasis grow at an abnormally fast rate, causing a buildup of lesions that tend to burn and itch. While the real cause of psoriasis is not known, genetics are believed to play a major role in its development. According to the National Psoriasis Foundation, psoriasis affects 7.5 million people in the United States.
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively "OWC" or the "Company"
conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information, visit: http://www.owcpharma.com/
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact Information:
In Israel:
Ziv Turner, Chief Executive Officer - One World Cannabis Ltd.
Email: ziv.turner@owcpharma.com
Tel: +972-(0)3-7582659
SOURCE OWC Pharmaceutical Research Corp.
Copyright © 2016 PR Newswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
OWC Pharmaceutical Research Corp Signs Agreement With US Partner for Funding in Advance of Future Royalties
Sep 30, 2016
OTC Disclosure & News Service
-
OWC Pharmaceutical Research Corp Signs Agreement With US Partner for Funding in Advance of Future Royalties
Initial Focus Will Be Commercialization Of Company's Topical Psoriasis Treatment
PR Newswire
PETACH TIKVA, Israel, September 30, 2016
PETACH TIKVA, Israel, September 30, 2016 /PRNewswire/ --
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company"
, an Israeli-based developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced it signed an agreement for $300,000 with Medmar LLC ("Medmar" . (Logo: http://photos.prnewswire.com/prnh/20150311/734965-a )
(Logo: http://photos.prnewswire.com/prnh/20150311/734965-b )
According to the terms of the agreement:
The funds will be allocated to complete the development of the Company's proprietary psoriasis cream;
Medmar will have exclusive right to manufacture, produce, publicize, promote and market OWC's Licensed Products in any state in the U.S;
The loan is non-interest bearing and will be repaid from royalties generated by the sale of OWC licensed products.
Commenting on his investment, Steve Weinstein, CEO of Medmar said, "Medmar has been anxious to advance cannabis as medicine, however US regulation makes it very difficult for companies here to actively pursue any type of development in the sector; fortunately, the environment in Israel is more favorable to the industry."
Mr. Weinstein went on to say, "We learned about OWC as they are one of only a handful of companies taking a true clinical approach to the research and development of medical cannabis, and this was important to us. Once we saw the preliminary results for their clinical studies, particularly in the field of psoriasis, we decided to make an investment and partner with them."
Mordechai Bignitz, OWC's Chairman and CEO, also commented on the announcement, "As we continue to make progress in our clinical trials for multiple myeloma, psoriasis and fibromyalgia, we are excited to partner with MedMar as we prepare to bring products to market. Their confidence in the potential for the commercialization of our research is clearly evident in the terms of this agreement."
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively "OWC" or the "Company"
conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information, visit: http://www.owcpharma.com/
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact Information:
In Israel:
Ziv Turner, Chief Executive Officer - One World Cannabis Ltd.
Email: ziv.turner@owcpharma.com
Tel: +972-(0)3-7582659
In the United States:
Jeffrey Friedland
Email: Jfriedland@owcpharma.com
Tel: +1-646-450-8909
SOURCE OWC Pharmaceutical Research Corp.
Copyright © 2016 PR Newswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
OWC Pharmaceuticals Corp to Present at Israeli Advanced Technology Industry's BioMed Conference
Apr 26, 2016
OTC Disclosure & News Service
-
OWC Pharmaceuticals Corp to Present at Israeli Advanced Technology Industry's BioMed Conference
Selected To Present at the Start-ups Hall Booth #80
PR Newswire
PETACH TIKVA, Israel, April 26, 2016
PETACH TIKVA, Israel, April 26, 2016 /PRNewswire/ --
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company"
, an Israeli-based developer of cannabinoid-based therapies targeting a variety of different indications, today announced that it was selected to present at the 2016 Israeli Advanced Technology Industries (IATI) BioMed Conference (the "Conference" . (Logo: http://photos.prnewswire.com/prnh/20150311/734965-a )
(Logo: http://photos.prnewswire.com/prnh/20150311/734965-b )
The Conference is a part of Israel's 15th National Life Sciences and Technology Week, and is being held May 24th to 26th at the David Intercontinental Hotel in Tel Aviv, Israel. The Company is currently scheduled to present at Booth #80 on the 24th .
The Biomed conference is the preeminent event for the Israeli life sciences industry, attracting leading members of the healthcare industry from around the globe. It comprises group discussions, panel presentations, product demonstrations and networking opportunities, all designed to encourage business collaborations. Attendees are able to experience firsthand the entrepreneurial spirit which is a basis of Israel's vibrant life sciences community. Prior conferences have hosted over 6,000 industry senior executives, scientists, and engineers, including approximately 1,000 participants from over 45 countries and in excess of 4,500 one-on-one meetings.
Ziv Turner, OWC Israel CEO stated, "We are so proud to have been selected by IATI to participate in BioMed. This is the biggest and most established annual meeting of the Israeli life science industry. The conference attracts investors and companies from around the world who are looking for innovation and ground breaking technology, providing us with the opportunity to meet one on one with potential investors, strategic partners and collaborators."
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively "OWC" or the "Company"
conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. The Company is a wholly owned subsidiary of OWC Pharmaceutical Research Corp. (OTCQB: OWCP). For more information, visit: http://www.owcpharma.com/ Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact Information:
In Israel:
Ziv Turner, Chief Executive Officer - One World Cannabis Ltd.
Email: ziv.turner@owcpharma.com
Tel: +972-(0)3-7582659
In the United States:
Jeffrey Friedland
Email: Jfriedland@owcpharma.com
Tel: +1-(646)-450-8909
SOURCE OWC Pharmaceutical Research Corp.
Copyright © 2016 PR Newswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
(0)
(0)Scroll down for more posts ▼
